Detalhe da pesquisa
1.
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Br J Haematol;
2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724457
2.
Ponatinib-review of historical development, current status, and future research.
Am J Hematol;
2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727135
3.
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Cancer;
2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38809547
4.
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome.
Clin Lymphoma Myeloma Leuk;
2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38777652
5.
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Cell Rep Med;
: 101585, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38781960
6.
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
Leuk Lymphoma;
: 1-10, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38749022
7.
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions.
J Hematol Oncol;
17(1): 32, 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38734670
8.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
JAMA;
2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722621
9.
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?
Expert Rev Hematol;
17(6): 189-191, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38726703
10.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica;
2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695144
11.
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Leuk Lymphoma;
: 1-11, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38712673
12.
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
Cancer;
2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38804723
13.
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.
NEJM Evid;
3(6): EVIDoa2300362, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38804782
14.
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN.
Leuk Res;
142: 107518, 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744144
15.
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
Int J Hematol;
2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748089
16.
Methodological challenges in the development of endpoints for myelofibrosis clinical trials.
Lancet Haematol;
11(5): e383-e389, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38604205
17.
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Am J Hematol;
2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607091
18.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Blood Adv;
2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607410
19.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer;
2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
20.
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
Am J Hematol;
2024 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38613831